SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Geom Therapeutics, Inc., a privately held biopharmaceutical company
Dirk Thye, M.D., Executive Chairman of Geom Therapeutics, Inc., said, "We are very excited to introduce our two novel compounds to the infectious diseases scientific community. GT-1 and GT-055 are intended for the treatment of multidrug-resistant gram-negative infections, including infections caused by species of Acinetobacter and Pseudomonas, which are among the most critical bacterial threats to human health. Geom's presentations at the ASM Microbe 2018 meeting summarize key research and development results and provide the foundation for GT-1 to enter human clinical trials in the second half of 2018."
Details of the ASM Microbe 2018 presentations are as follows:
Friday, June 8th
Oral Presentation Session 012 - New Agents Discovery Summary Session: Early New Antimicrobial Agents (8:45 a.m. – 10:45 a.m.)
Oral Presentation Session 147 - Trouble-shooting Preclinical Antibacterial Development: A Consensus PK/PD Approach (2:45 p.m. – 3:00 p.m.)
Saturday, June 9th
Poster Presentation Session 233 - AAR04 - Antimicrobial PK/PD & General Pharmacology: in vivo Studies (11:00 a.m. – 1:00 p.m.)
Sunday, June 10th
Poster Presentation Session 412 - AAR08 - New Antimicrobial Agents and New Research Technologies: New Cephalosporins, Penems, and Carbapenems (12:45 p.m. – 2:45 p.m.)
Copies of all poster presentations will be available on the Geom website following the ASM Microbe meeting: http://www.Geomtherapeutics.com/.
GT-1, a novel siderophore cephalosporin antibiotic, is being developed for the treatment of MDR Gram-negative bacterial infections. GT-1 is actively transported into Gram-negative cells by exploiting iron uptake systems that use low molecular weight iron-binding molecules, known as siderophores, to transport iron into the cells. This "Trojan Horse" strategy facilitates the uptake of GT-1 into the bacterial periplasmic space in high concentrations where GT-1 binds to its penicillin-binding protein targets and disrupts cell wall synthesis, leading to cell death. This increased transport into bacterial cells potentiates activity against Gram-negative bacteria, including MDR Acinetobacter spp. and P. aeruginosa. All IND-enabling studies have been completed for GT-1 and Geom plans to submit an IND to the FDA in 2H 2018. For more information about GT-1, please visit http://www.geomtherapeutics.com/GT-1.
About Geom Therapeutics
Geom Therapeutics is a biotechnology company focused on the development of novel antibiotics for MDR gram-negative infections. Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1. GT-1, our lead product candidate, a cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against gram-negative pathogens and is in development for the treatment of serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. We are conducting a Phase 1 study with GT-1 in partnership with The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH). We have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Our mission is to improve patients' lives by developing novel antibiotics to treat resistant infections for which there are no available therapies. For more information, please visit www.geomtherapeutics.com.
Media Contact: Brendan Hannah firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/geom-therapeutics-to-present-data-from-antibiotic-drug-development-programs-at-asm-microbe-300655536.html
SOURCE Geom Therapeutics, Inc.
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All